Cargando…

The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD

BACKGROUND: Navafenterol (AZD8871) belongs to a new class of bronchodilator, the single-molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD. This study aimed to evaluate the efficacy, pharmacokinetics and safety of navafenterol versus placebo and an active comparator tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Dave, Beier, Jutta, Astbury, Carol, Belvisi, Maria G., Da Silva, Carla A., Jauhiainen, Alexandra, Jimenez, Eulalia, Lei, Alejhandra, Necander, Sofia, Smith, Jaclyn A., Wählby Hamrén, Ulrika, Xin, Wenjing, Psallidas, Ioannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2022
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989052/ https://www.ncbi.nlm.nih.gov/pubmed/34503985 http://dx.doi.org/10.1183/13993003.00972-2021

Ejemplares similares

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
por: Singh, Dave, et al.
Publicado: (2020)

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies
por: Balaguer, Victor, et al.
Publicado: (2020)

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
por: Jimenez, Eulalia, et al.
Publicado: (2020)

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021)

Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial
por: Brown, Mary N., et al.
Publicado: (2019)

Abediterol, a novel long-acting β(2)-agonist: bronchodilation, safety, tolerability and pharmacokinetic results from a single-dose, dose-ranging, active-comparator study in patients with COPD
por: Beier, Jutta, et al.
Publicado: (2016)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
por: Pascoe, Steven, et al.
Publicado: (2016)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD
por: Voorham, Jaco, et al.
Publicado: (2019)

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
por: Beier, Jutta, et al.
Publicado: (2017)

Impact of bronchodilator therapy on exercise tolerance in COPD
por: Aguilaniu, B
Publicado: (2010)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Flow and volume response to bronchodilator in patients with COPD
por: Matteo, Vigna, et al.
Publicado: (2018)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

Stepwise management of COPD: What is next after bronchodilation?
por: Miravitlles, Marc, et al.
Publicado: (2023)

The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD
por: Singh, Dave, et al.
Publicado: (2018)

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
por: Prothon, Susanne, et al.
Publicado: (2019)

Airway wall thickness is increased in COPD patients with bronchodilator responsiveness
por: Kim, Victor, et al.
Publicado: (2014)

Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity
por: Barjaktarevic, Igor, et al.
Publicado: (2018)

Bronchodilators for hyperinflation in COPD associated with biomass smoke: clinical trial
por: Ramírez-Venegas, Alejandra, et al.
Publicado: (2019)

Is it Reasonable to Start Bronchodilator Treatment Before Confirming the Diagnosis of COPD?
por: Figueira-Gonçalves, Juan Marco, et al.
Publicado: (2023)

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers
por: Cullberg, Marie, et al.
Publicado: (2018)

EP(4) receptor as a new target for bronchodilator therapy
por: Buckley, James, et al.
Publicado: (2011)

The Bronchoprotective Effects of Dual Pharmacology, Muscarinic Receptor Antagonist and β(2) Adrenergic Receptor Agonist Navafenterol in Human Small Airways
por: Jude, Joseph Antony, et al.
Publicado: (2023)

Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment
por: Spielmanns, Marc, et al.
Publicado: (2022)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

Bronchodilators in COPD: Impact of β-agonists and anticholinergics on severe exacerbations and mortality
por: Salpeter, Shelley R
Publicado: (2007)

Bronchodilator response of advanced lung function parameters depending on COPD severity
por: Jarenbäck, Linnea, et al.
Publicado: (2016)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

Uncovering the beneficial effects of inhaled bronchodilator in COPD: beyond forced spirometry
por: Neder, José Alberto, et al.
Publicado: (2019)

Data Reproducibility and Effectiveness of Bronchodilators for Improving Physical Activity in COPD Patients
por: Minakata, Yoshiaki, et al.
Publicado: (2020)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

Acute Effect of Bronchodilator on Intrathoracic Airway Wall Compliance in COPD Patients
por: Pini, Laura, et al.
Publicado: (2022)

Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD
por: Kardos, Peter, et al.
Publicado: (2016)

The future of bronchodilation: looking for new classes of bronchodilators
por: Cazzola, Mario, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vgu3pnu479btngqkjvt374rrqu